Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
Public ClinicalTrials.gov record NCT03761069. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, non-randomized, Phase 1b study to evaluate the safety, pharmacokinetics (PK) profiles, and preliminary evidence of antitumor activity of PTC299 and the metabolite, O-desmethyl PTC299, in participants with relapsed/refractory acute myeloid leukemia (AML) who have exhausted standard available therapies known to provide clinical benefit. The study is designed as a series of cohort-based dose escalations. For each cohort, a minimum of 3 evaluable participants with PK and safety data will be assessed. Additional participants will be recruited if additional PK data are needed to assess mean exposure based on the observed variability.
Study identification
- NCT ID
- NCT03761069
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 29, 2018 (Actual)
- Primary completion
- Dec 28, 2021 (Actual)
- Completion
- Dec 28, 2021 (Actual)
- Last update posted
- Feb 2, 2022
2018 – 2021
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Center | Aurora | Colorado | 80012 | — |
| Yale University | New Haven | Connecticut | 06510 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Rutgers, Cancer Institute of NJ | New Brunswick | New Jersey | 08903 | — |
| Columbia | New York | New York | 10032 | — |
| University of Rochester MC | Rochester | New York | 14642 | — |
| Duke Cancer Center | Durham | North Carolina | 27710 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45236 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Rhode Island, Miriam Hospital | Providence | Rhode Island | 02903 | — |
| SCRI Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Oncology, P.A. | Austin | Texas | 78705 | — |
| Texas Oncology, P.A. | Fort Worth | Texas | 76104 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology, P.A. - San Antonio Medical Center | San Antonio | Texas | 78240 | — |
| Swedish Cancer Institute | Seattle | Washington | 91804 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03761069, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 2, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03761069 live on ClinicalTrials.gov.